Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe and Australia[1] because of allergic reactions.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Topical, rectal |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.017.683 |
Chemical and physical data | |
Formula | C12H17NO3 |
Molar mass | 223.272 g·mol−1 |
3D model (JSmol) |
|
| |
|
Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns,[citation needed] and itching. Suppositories containing bufexamac in combination with local anaesthetics are used against haemorrhoids.[2]
Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it a non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.[3] Furthermore, bufexamac was identified as a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10).[4]
Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.[5] As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.[6]